Literature DB >> 28058554

Prognosis of Intrahepatic Cholangiocarcinomas with HBV Infection is Better than Those with Hepatolithiasis After R0 Liver Resection: A Propensity Score Matching Analysis.

Qing Wang1,2, Jun Li1, Zhengqing Lei1, Dong Wu1, Anfeng Si1, Kui Wang1, Yizhou Wang1, Xuying Wan3, Wan Yee Lau1,4, Feng Shen5.   

Abstract

BACKGROUND: The impact of different causative factors of intrahepatic cholangiocarcinoma (ICC) on disease outcome remains largely unknown. This study aimed to evaluate the prognosis of ICC patients with different pathogenic factors after hepatectomy.
METHODS: Data of 731 consecutive patients undergoing R0 liver resection for ICC at The Eastern Hepatobiliary Surgery Hospital between 2004 and 2010 were analyzed. These patients were divided into the hepatitis B virus-related (HBV-ICC, n = 519), hepatolithiasis-related (stone-ICC, n = 87), HBV plus hepatolithiasis-related (HBV/stone-ICC, n = 45), and other etiologies-related (other-ICC, n = 80) ICC groups. Propensity score matching (PSM) was used to eliminate the baseline differences between these groups.
RESULTS: In these four groups, the 5-year tumor recurrence and overall survival (OS) rates were 75.4, 90.3, 83.0 and 81.9%, and 32.7, 16.3, 17.7 and 22.6%, respectively. The significant differences in recurrence and OS were identified between the HBV- and stone-ICC groups (both p < 0.001). In these two groups, most of the independent prognostic predictors were similar, but tumor diameter >5 cm was demonstrated as a risk factor in the HBV-ICC patients only, and surgical margin <1 cm and human epidermal growth factor receptor 2-positive were demonstrated as risk factors in the stone-ICC patients only. With PSM, 75 patients in each of the HBV- and stone-ICC cohorts were created, and the 5-year recurrence and OS rates were 69.9 versus 88.6, and 34.6 versus 19.2%, respectively (p = 0.017, 0.027).
CONCLUSION: Patients with HBV-ICC achieved better outcomes than those with stone-ICC. This prognostic difference was probably associated with biological malignant invasiveness rather than tumor stage.

Entities:  

Mesh:

Year:  2017        PMID: 28058554     DOI: 10.1245/s10434-016-5751-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

Review 1.  Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis.

Authors:  Seogsong Jeong; Guijuan Luo; Zhi-Heng Wang; Meng Sha; Lei Chen; Qiang Xia
Journal:  Hepatol Int       Date:  2018-06-26       Impact factor: 6.047

2.  Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study.

Authors:  Xu-Feng Zhang; Jeffery Chakedis; Fabio Bagante; Eliza W Beal; Yi Lv; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

Review 3.  Surgical Approach to Recurrent Cholangiocarcinoma.

Authors:  Hauke Lang
Journal:  Visc Med       Date:  2020-12-21

4.  Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma.

Authors:  Tao Wang; Wanxiang Wang; Jinfu Zhang; Xianwei Yang; Shu Shen; Wentao Wang
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

5.  Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.

Authors:  Ying-Ying Liang; Shuo Shao; Sichi Kuang; Jingbiao Chen; Jing Zhou; Bingjun He; Linqi Zhang; Yao Zhang; Kathryn J Fowler; Jin Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-04

6.  High serum gamma-glutamyl transpeptidase concentration associates with poor postoperative prognosis of patients with hepatitis B virus-associated intrahepatic cholangiocarcinoma.

Authors:  Bo Zhang; Shuang Liu; Binghai Zhou; Lei Guo; Hui Li; Jiuliang Yan; Wentao Zhang; Mincheng Yu; Zheng Chen; Yongfeng Xu; Yongsheng Xiao; Qinghai Ye
Journal:  Ann Transl Med       Date:  2021-01

7.  Double-Negative α-Fetoprotein and Carbohydrate Antigen 19-9 Predict a Good Prognosis in Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.

Authors:  Xiaoyun Zhang; Yongjie Zhou; Zhenru Wu; Wei Peng; Chuan Li; Lvnan Yan; Jiayin Yang; Tianfu Wen
Journal:  Clin Transl Gastroenterol       Date:  2021-11-09       Impact factor: 4.488

8.  Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection.

Authors:  Seogsong Jeong; Qingbao Cheng; Lifeng Huang; Jian Wang; Meng Sha; Ying Tong; Lei Xia; Longzhi Han; Zhifeng Xi; Jianjun Zhang; Xiaoni Kong; Jinyang Gu; Qiang Xia
Journal:  BMC Cancer       Date:  2017-07-03       Impact factor: 4.430

9.  Transarterial Chemoembolization: A Favorable Postoperative Management to Improve Prognosis of Hepatitis B Virus-associated Intrahepatic Cholangiocarcinoma after Surgical Resection.

Authors:  Seogsong Jeong; Bo Zheng; Jian Wang; Jiachang Chi; Ying Tong; Lei Xia; Ning Xu; Jianjun Zhang; Xiaoni Kong; Jinyang Gu; Qiang Xia
Journal:  Int J Biol Sci       Date:  2017-09-21       Impact factor: 6.580

10.  Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients.

Authors:  Ping Tao; Lijie Ma; Ruyi Xue; Haijie Wang; Si Zhang
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.